Spinomix raises $3 million in A round

Molecular diagnostic technologies company Spinomix S.A. (Lausanne, Switzerland) raised $3 million in a series A round led by new investor Debiopharm Group (Lausanne, Switzerland). Spinomix's founders and an undisclosed private U.S. investor group also participated. Spinomix is developing automated and miniaturized systems for the extraction, manipulation and detection of biological materials for sample preparation. The company is using its FibroTram fibrinogen-based technology to separate targeted cells and molecules along with its MagPhase automated sample preparation platform, which incorporates magnetic nanoparticles and microfluidics. ...